FIGURE 3.

Potential inhibitors of SHH signaling for the treatment of MBs. (A) Vismodegib and sonidegib, drugs that inhibit SHH activation by SMO on the surface of the tumor cell, have been approved for treating MB patients. (B) Inside the tumor cell, silmitasertib (CX-4945) blocks the kinase activity of CK2, which results in dephosphorylation of GLI proteins, while GANT61, ATO, and GlaB are capable of preventing GLI-mediated transcription. Panobinostat, an HDAC inhibitor, reduces GLI activity via regulation of its acetylation. CK2, Casein kinase 2; GANT61, GLI antagonist 61; ATO, Arsenic trioxide; GlaB, Glabrescione B.